Expanded authorization for Nuvaxovid COVID-19 vaccine in Canada

Adding to an Emergency Use Authorization (EUA) in the USA for the vaccine last month, US biotech Novavax (Nasdaq: NVAX) says that Health Canada has granted expanded authorization for Nuvaxovid (COVID-19 vaccine (Recombinant protein, adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous booster in adults aged 18 and older.

Health Canada previously authorized Nuvaxovid as a primary series in adults aged 18 and older in February 2022. Novavax filed in Canada for the vaccine's use as a primary series in adolescents aged 12 through 17 in June 2022.

"Canadians now have access to our protein-based Nuvaxovid COVID-19 vaccine as an adult booster," said Stanley Erck, president and chief executive of Novavax, adding: "With the winter months upon us, it's important to have options for vaccination to help protect against COVID-19."